Seegene Inc - Asset Resilience Ratio
Seegene Inc (096530) has an Asset Resilience Ratio of 24.96% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Seegene Inc (096530) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how Seegene Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Seegene Inc balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Seegene Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Seegene Inc (096530) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩316.04 Billion | 24.96% |
| Total Liquid Assets | ₩316.04 Billion | 24.96% |
Asset Resilience Insights
- Good Liquidity Position: Seegene Inc maintains a healthy 24.96% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Seegene Inc Industry Peers by Asset Resilience Ratio
Compare Seegene Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Seegene Inc (2012–2025)
The table below shows the annual Asset Resilience Ratio data for Seegene Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 29.16% | ₩360.33 Billion ≈ $244.19 Million |
₩1.24 Trillion ≈ $837.48 Million |
+7.34pp |
| 2024-12-31 | 21.81% | ₩262.92 Billion ≈ $178.17 Million |
₩1.21 Trillion ≈ $816.80 Million |
-4.60pp |
| 2023-12-31 | 26.41% | ₩330.50 Billion ≈ $223.98 Million |
₩1.25 Trillion ≈ $848.09 Million |
-17.00pp |
| 2022-12-31 | 43.41% | ₩603.78 Billion ≈ $409.17 Million |
₩1.39 Trillion ≈ $942.51 Million |
+11.63pp |
| 2021-12-31 | 31.78% | ₩473.45 Billion ≈ $320.85 Million |
₩1.49 Trillion ≈ $1.01 Billion |
+2.43pp |
| 2020-12-31 | 29.35% | ₩321.26 Billion ≈ $217.71 Million |
₩1.09 Trillion ≈ $741.78 Million |
+1.75pp |
| 2019-12-31 | 27.60% | ₩54.01 Billion ≈ $36.60 Million |
₩195.72 Billion ≈ $132.63 Million |
+4.73pp |
| 2018-12-31 | 22.87% | ₩37.46 Billion ≈ $25.39 Million |
₩163.81 Billion ≈ $111.01 Million |
+0.02pp |
| 2017-12-31 | 22.85% | ₩37.66 Billion ≈ $25.52 Million |
₩164.84 Billion ≈ $111.71 Million |
-12.70pp |
| 2016-12-31 | 35.55% | ₩73.80 Billion ≈ $50.01 Million |
₩207.62 Billion ≈ $140.70 Million |
+22.05pp |
| 2015-12-31 | 13.50% | ₩26.19 Billion ≈ $17.75 Million |
₩194.05 Billion ≈ $131.50 Million |
+5.12pp |
| 2014-12-31 | 8.38% | ₩11.60 Billion ≈ $7.86 Million |
₩138.45 Billion ≈ $93.83 Million |
+1.40pp |
| 2013-12-31 | 6.97% | ₩9.00 Billion ≈ $6.10 Million |
₩129.04 Billion ≈ $87.45 Million |
-2.75pp |
| 2012-12-31 | 9.73% | ₩8.13 Billion ≈ $5.51 Million |
₩83.62 Billion ≈ $56.67 Million |
-- |
About Seegene Inc
Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection … Read more